A Context-Aware Target Engagement and Pharmacodynamic Biomarker Resource to Accelerate Drug Discovery and Development

Confirming target engagement in tumor experimental models remains a major challenge in oncology drug development. Pharmacodynamic biomarkers can help address this, but few systematic resources link drug targets to candidate biomarkers. We developed TargetTrace, a comprehensive resource to identify and prioritize pharmacodynamic biomarkers across nine key target classes, including transcription factors/cofactors, kinases, phosphatases, ubiquitin ligases, deubiquitinases, acetyltransferases, deacetylases, methyltransferases, and demethylases. Biomarker candidates were gathered from curated molecular interaction resources and refined using external annotations to improve accuracy. For enzyme targets with measurable substrate changes, we applied a two-agent large language model workflow, followed by manual review, to harmonize antibody information from the antibody resources and ensure that the selected biomarkers are measurable with existing laboratory tests. From more than 92,000 input interactions and over 2,300 targets, we compiled 71,323 target-biomarker relationships involving 2,270 potential drug targets, encompassing both transcription factor/cofactor-target gene and enzyme-substrate interactions. Commercial antibodies were available for over 1,400 biomarkers, supporting laboratory validation. This resource provides a structured and reusable resource for systematic identification and prioritization of pharmacodynamic biomarkers in oncology.